Iambic Therapeutics, Inc. (IAM) revenue by segment
IAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$14.76+0.54 (+3.80%)
Close on Nov 18, 2026Market cap –P/E –Yield –
See a number that looks wrong?
Close on Nov 18, 2026Market cap –P/E –Yield –
See a number that looks wrong?